Advertisement

Chemotherapy

  • G. Stoter
  • C. J. Rodenburg
Part of the Clinical Practice in Urology book series (PRACTICE UROLOG)

Abstract

The history of cancer chemotherapy started with the incidental discovery that nitrogen mustard was cytotoxic to lymphoid malignancies. The initial enthusiasm was soon tempered by the observation that most responses were short-lived due to the development of drug resistance.

Keywords

Testicular Cancer Renal Cell Cancer Adoptive Immunotherapy Nitrogen Mustard Urologic Malignancy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Einhorn LH, Donohue JP (1977) Cisdiamminedichloroplatinum, vinblastine and bleomycin combi- nation chemotherapy in disseminated testicular cancer. Ann Intern Med 87: 293–298PubMedGoogle Scholar
  2. Goldie JH, Coldman AJ (1984) The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 44: 3643–3653PubMedGoogle Scholar
  3. Groopman JE et al. (1987) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the Acquired Immunodeficiency Syndrome. N Engl J Med 317: 593–598PubMedCrossRefGoogle Scholar
  4. Li MC, Whitmore Jr WF, Golbey R, Grabstald H (1960) Effects of combined drug therapy on metastatic cancer of the testis. JAMA 174: 145–153Google Scholar
  5. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, De Vita Jr, VT (1986) Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol 9: 1295–1306Google Scholar
  6. National Institutes of Health (1986) Consensus development panel on adjuvant chemotherapy and endocrine therapy for breast cancer. Introduction and conclusions. NCI Monographs 1: 1–17Google Scholar
  7. Nienhuis AW et al. (1987) Recombinant human GM-CSF shortens the period of neutropenia after autologous bone marrow transplantation in a primate model. J Clin Invest 80: 573–577PubMedCrossRefGoogle Scholar
  8. Rosenberg SA, Lotze MT, Muul LM et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889–897PubMedCrossRefGoogle Scholar
  9. Samuels ML, Holoye PY, Johnson DE (1975) Bleomycin combination chemotherapy in the management of testicular neoplasia. Cancer 36: 318–326PubMedCrossRefGoogle Scholar
  10. Scher H, Yagoda A, Herr H et al. (1988) Neoadjuvant M-VAC (methotrexate, vinblastine, adriamycin and cisplatin): effect on the primary bladder lesion. J Urol 139: 470–474PubMedGoogle Scholar
  11. Stoter G, Sylvester R, Sleijfer DT, ten Bokkel Huinink WW, Kaye SB, Jones WG, van Oosterom AT, Vendrik CPJ, Spaander P, de Pauw M (1987a) Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Cancer Multiinstitutional Phase III Study. Cancer Res 47: 2714–2718Google Scholar
  12. Stoter G, Splinter TAW, Child JA, Fossâ SD, Denis L, van Oosterom AT, de Pauw M, Sylvester R for the European Organization for Research on Treatment of Cancer Genito-urinary Group (1987b) Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol 137: 663–667Google Scholar
  13. West WH, Tauer KW, Yannelli JR et al. (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898–905PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • G. Stoter
  • C. J. Rodenburg

There are no affiliations available

Personalised recommendations